RecruitingPhase 1NCT06945419

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes


Sponsor

Eli Lilly and Company

Enrollment

216 participants

Start Date

Apr 23, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new experimental weight loss medication called LY4086940 in people who are overweight or obese, with or without type 2 diabetes, to see how safe it is and how it affects weight. **You may be eligible if...** - Your weight has been stable (no major changes) for the past 3 months - You are overweight or obese (BMI of 27 or higher for most parts of the study) - For the type 2 diabetes part: you have type 2 diabetes with HbA1c between 7.0% and 10.5% - You are otherwise in good health (for the healthy volunteer part: BMI 22–35) **You may NOT be eligible if...** - You have had a heart attack, stroke, or other serious cardiovascular event in the past 6 months - You have significant liver, kidney, or gastrointestinal disease - You are pregnant or planning to become pregnant - You have had bariatric (weight loss) surgery - You are on certain medications that could interact with the study drug Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY4086940

Administered orally

DRUGPlacebo

Administered orally

DRUGLY4086940

Administered IV


Locations(6)

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Clinical Pharmacology of Miami

Miami, Florida, United States

CenExel iResearch, LLC

Decatur, Georgia, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States

Endeavor Clinical Trials

San Antonio, Texas, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06945419


Related Trials